Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia

Shigematsu, Akio; Kondo, Takeshi; Yamamoto, Satoshi; Sugita, Junichi; Onozawa, Masahiro; Kahata, Kaoru; Endo, Tomoyuki; Shiratori, Soichi; Ota, Shuichi; Obara, Masato; Wakasa, Kentaro; Takahata, Mutsumi; Takeda, Yukari; Tanaka, Junji; Hashino, Satoshi; Nishio, Mitsufumi; Koike, Takao; Asaka, Masahiro; Imamura, Masahiro

Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia

Shigematsu, Akio; Kondo, Takeshi; Yamamoto, Satoshi et al.

Biology of Blood and Marrow Transplantation, 2008, 14(5), 568-575

Permalink : https://hdl.handle.net/2115/62833

このアイテムのアクセス数:1,126件（2026-08-13 01:03 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
36_1-s2.0-S1083879108001079-main	pdf	253 KB	758

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/62833
タイトル	Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia
著者	Shigematsu, Akio ; Kondo, Takeshi ; Yamamoto, Satoshi ; Sugita, Junichi ; Onozawa, Masahiro ; Kahata, Kaoru ; Endo, Tomoyuki ; Shiratori, Soichi ; Ota, Shuichi ; Obara, Masato ; Wakasa, Kentaro ; Takahata, Mutsumi ; Takeda, Yukari ; Tanaka, Junji ; Hashino, Satoshi ; Nishio, Mitsufumi ; Koike, Takao ; Asaka, Masahiro ; Imamura, Masahiro
e-Rad_Researcher 30037428 著者名 Shigematsu, Akio
e-Rad_Researcher 70333606 著者名 Kondo, Takeshi
著者名 Yamamoto, Satoshi
e-Rad_Researcher 70755694 著者名 Sugita, Junichi
e-Rad_Researcher 70455632 著者名 Onozawa, Masahiro
著者名 Kahata, Kaoru
著者名 Endo, Tomoyuki
著者名 Shiratori, Soichi
著者名 Ota, Shuichi
著者名 Obara, Masato
著者名 Wakasa, Kentaro
著者名 Takahata, Mutsumi
著者名 Takeda, Yukari
e-Rad_Researcher 50250452 著者名 Tanaka, Junji
e-Rad_Researcher 60271665 著者名 Hashino, Satoshi
e-Rad_Researcher 10322801 著者名 Nishio, Mitsufumi
e-Rad_Researcher 80146795 著者名 Koike, Takao
e-Rad_Researcher 10113507 著者名 Asaka, Masahiro
e-Rad_Researcher 20160062 著者名 Imamura, Masahiro
言語	英語
キーワード	VP-16
	Acute lymphoblastic leukemia
	Adult
	Hematopoietic stem cell transplantation
	Conditioning regimen
発行日	2008-05
出版者	Elsevier
収録物名	Biology of Blood and Marrow Transplantation
巻(号)	14(5)
ページ	568-575
抄録	We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph+) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph+ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN	1083-8791
関連情報	PMID 18410899
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1016/j.bbmt.2008.02.018